Dr. Reynolds received his BA in Biology from The University of Texas at Austin, his MD from UT Southwestern Medical School in Dallas, TX, his PhD (Cell Biology) from UT Austin, and his pediatrics training at the National Naval Medical Center. His postdoctoral fellowship was in cancer immunology at UT Southwestern Medical School, Dallas, TX. His areas of research interest are:
- retinoids as tumor-selective differentiation or cytotoxic agents,
- mechanisms of drug resistance and drugs to modulate resistance in childhood and adult cancers,
- development of novel preclinical testing models for childhood cancer drug development, and
- clinical trials testing novel therapeutic approaches for cancer.
Dr. Reynolds is the Cancer Center Director for the School of Medicine, Texas Tech University Health Sciences Center (TTUHSC), and is Director of the South Plains Oncology Consortium (SPOC). He is a Professor of Cell Biology & Biochemistry, Pediatrics, and Medicine at the TTUHSC School of Medicine.
Dr. Reynolds is a member of the steering committees for neuroblastoma and translational research for the Children's Oncology Group. He is a special government employee with the FDA and a founding member of the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee for the FDA. He is a chartered member of the Drug Discovery and Molecular Pharmacology Grant Study Section for the National Cancer Institute and a member of the Best Pharmaceuticals for Children Act prioritization panel for the National Institute for Child Health and Development.
Dr. Reynolds sponsors multiple FDA Investigational New Drug (IND) applications and has active Rapid Access to Intervention Discovery (RAID), RO1, grant support from the National Cancer Institute (NCI) and the Cancer Prevention & Research Institute of Texas. He is the Principal Investigator of the NCI-funded Pediatric Preclinical Testing Program (PPTP) cell culture laboratory. He is also the Principal Investigator of the Texas Cancer Cell Repository and is the site PI for the Texas Cancer Research Biobank and the Texas Cancer Clinical Trials Network. His laboratory serves as the Cell Line Repository and the Ewing's Family Tumors Preclinical Testing Lab for the Children's Oncology Group. Dr. Reynolds is an author or co-author of more than 200 scientific papers and is an Associate Editor for Clinical Cancer Research.